Revance Therapeutics News

Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)

TipRanksApr 23 05:59 ET

Revance Therapeutics Analyst Ratings

BenzingaFeb 29 15:16 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)

TipRanksFeb 29 11:01 ET

Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)

TipRanksFeb 29 07:11 ET

Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)

TipRanksFeb 29 06:40 ET

Revance Therapeutics (RVNC) Gets a Buy From Barclays

TipRanksFeb 29 02:45 ET

Revance Therapeutics: Strategic Pivot and Growth Potential Justify Buy Rating

TipRanksFeb 28 18:45 ET

Revance Therapeutics Analyst Ratings

BenzingaFeb 23 09:30 ET

Barclays Remains a Buy on Revance Therapeutics (RVNC)

TipRanksFeb 23 03:05 ET

Revance Therapeutics Analyst Ratings

BenzingaJan 29 15:03 ET

Revance Therapeutics Analyst Ratings

BenzingaJan 29 07:26 ET

Barclays Keeps Their Buy Rating on Revance Therapeutics (RVNC)

TipRanksJan 29 05:07 ET

Stifel Nicolaus Sticks to Their Buy Rating for Revance Therapeutics (RVNC)

TipRanksJan 12 07:37 ET

Goldman Sachs Downgrades Revance Therapeutics to Neutral, Lowers Price Target to $8

BenzingaJan 9 10:03 ET

Revance Therapeutics Analyst Ratings

BenzingaJan 9 09:59 ET

Analysts Are Neutral on Top Healthcare Stocks: Revance Therapeutics (RVNC), Roche Holding AG (RHHVF)

TipRanksJan 9 08:40 ET

Buy Rating on Revance Therapeutics: Balancing Near-Term Challenges With Long-Term RHA Filler Potential

TipRanksJan 9 06:17 ET

Strong Buy Rating for Revance Therapeutics Amidst Promising Drug Prospects and Solid Financials

TipRanksJan 8 11:25 ET

Piper Sandler Keeps Their Buy Rating on Revance Therapeutics (RVNC)

TipRanksNov 29, 2023 06:36 ET

Revance Therapeutics Analyst Ratings

BenzingaNov 22, 2023 11:47 ET